1049 GMT - Investors are looking for evidence of GSK's pipeline progress as the patent for its HIV drug Dolutegravir will expire from 2028 in the U.S., Berenberg analysts say in a note. The British pharma giant's key growth drivers include its shingles vaccine Shingrix, its RSV shot Arexvy, HIV drugs Dovato, Cabenuva, Apretude and its lupus treatment Benlysta and asthma drug Nucala, the analyst say. GSK is expected to post sales and earnings growth in line with European non-obesity peers over the 2023-27 time period, driven by both its pharmaceuticals and vaccines units, Berenberg says. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 20, 2025 05:50 ET (10:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。